From: Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study
β
Hazard ratio
P value
LR
Clinical T stage (3 vs. 4)
1.23
3.43
0.05
DFS
TRG score (3/4 vs. 1/2)
1.36
3.90
0.00
1.11
3.04
0.01